Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$74.15M-$74.15MN/M vs Q3 2024 EPS Diluted-$0.43-$0.43N/M vs Q3 2024 Operating Income-$80,391,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$62,118,000N/M ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end